Can I resume apixaban (Eliquis) after removal of a tunneled Hickman line?

Resuming Apixaban After Tunneled Hickman Line Removal

Yes, you can resume apixaban (Eliquis) after removal of a tunneled Hickman line, typically starting 6-24 hours post-procedure for low bleeding risk removal, or 24-72 hours for higher bleeding risk scenarios, once adequate hemostasis is established.

Timing of Resumption

The timing for restarting apixaban depends on the bleeding risk assessment of the catheter removal procedure and achievement of hemostasis:

Low-to-Moderate Bleeding Risk Procedures

• Resume apixaban approximately 24 hours after the procedure if hemostasis is adequate 1
• For apixaban's twice-daily regimen, this means resuming the evening of the procedure day or the following morning 1
• The FDA label states that apixaban should be restarted "as soon as adequate hemostasis has been established" 2

Considerations for Hickman Line Removal

Tunneled central venous catheter removal (including Hickman lines) is generally considered a low-to-moderate bleeding risk procedure because:

• Surgical hemostasis can be achieved with direct pressure
• The site is compressible and accessible
• Bleeding complications, while possible, are typically manageable 1

Specific Resumption Protocol

For apixaban 5 mg twice daily (standard dosing):

• If the catheter is removed in the morning: Resume that evening if hemostasis is confirmed 1
• If removed in the afternoon/evening: Resume the following morning 1
• Ensure at least 6 hours have elapsed since the procedure 1

For apixaban 2.5 mg twice daily (reduced dosing):

• Follow the same timing principles as above 1

Critical Safety Considerations

Do NOT Resume If:

• Active bleeding is present at the catheter site 1
• Surgical contraindication exists (e.g., concerns about hemostasis, hematoma formation) 1
• Hemostasis has not been adequately established 2

Bridging Therapy

• Bridging with heparin or LMWH is NOT recommended for routine Hickman line removal 1
• Bridging should only be considered for patients at very high thrombotic risk, which should be determined by the underlying indication for anticoagulation, not the procedure itself 1, 3

If Resumption Must Be Delayed

When hemostasis concerns require delaying therapeutic anticoagulation beyond 24-72 hours:

• Consider prophylactic-dose LMWH (enoxaparin 40 mg daily or dalteparin 5,000 IU daily) starting 6 hours post-procedure 1
• Resume therapeutic apixaban at 24-72 hours post-procedure once bleeding risk resolves 1
• Administer the first therapeutic apixaban dose at least 12 hours after the last prophylactic LMWH dose 1

Monitoring Post-Resumption

• Observe the catheter site for signs of bleeding or hematoma formation in the first 24-48 hours after resuming apixaban 1
• No routine laboratory monitoring of apixaban levels is required 1, 4
• If renal function may have been affected by the patient's clinical condition, check creatinine clearance and adjust dosing accordingly 1

Common Pitfalls to Avoid

1. Over-conservative delays: Unnecessarily prolonged interruption increases thrombotic risk without proven bleeding benefit 1, 4
2. Inappropriate bridging: Bridging with heparin actually increases bleeding risk without reducing thrombotic events 1
3. Ignoring hemostasis status: Always confirm adequate hemostasis before resuming, regardless of time elapsed 2
4. Missing dose adjustments: Verify the patient is on the appropriate apixaban dose for their indication and renal function before resuming 1

The pharmacokinetic profile of apixaban supports this approach, with a half-life of approximately 12 hours and rapid absorption (peak levels at 3-4 hours), allowing for predictable anticoagulant effect upon resumption 5.